Polarean Imaging plc
04/30/2020 | Press release | Archived content
Total Voting Rights
Corporate News
Total Voting Rights
30 April 2020
Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, announces that the total number of shares in issue and total voting rights as at the date of this announcement is 161,295,607 ordinary shares of £0.00037 each.
The total issued share capital of the Company consists of 161,295,607 Ordinary Shares. This number may be used by Shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
| Polarean Imaging plc | https://www.polarean.com/www.polarean-ir.com |
| Richard Hullihen, Chief Executive Officer | Via Walbrook PR |
| SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
| David Hignell / Soltan Tagiev (Corporate Finance) | |
| Vadim Alexandre / Rob Rees (Corporate Broking) | |
| Walbrook PR |
Tel: +44 (0)20 7933 8780 or [email protected] |
| Paul McManus / Anna Dunphy |
Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001 |
« back to Corporate News
Latest News
-
Holding(s) in Company
11 September 2025 -
Submission of new Phase III study protocol to FDA for expanded indication of XENOVIEW
12 August 2025 -
Block Listing Six Monthly Return
24 July 2025
Corporate News
View About us
About Us
Share Price
Share Price
-
GBp
-
-
-
Annual Report & Account 2024 (inc. Notice of AGM)
Latest Annual Report
Important Dates
Important dates
09 Jun
Annual General Meeting
08 May
Final Results
Investor Alert
Sign up for Email Alerts
Investor Alert
Polarean Imaging plc published this content on April 30, 2020, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 15, 2025 at 10:35 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]